A trial fibrillation (AF), a disease associated with mortality, morbidity, and high costs, affects tens of millions of people worldwide and is increasing in prevalence. 1,2 Among the many risk factors that promote the development of AF, the most prominent are sex (more prevalent in men than women), old age (>60 years old), and hypertension. 2 Hypertension and aging lead to structural changes of the extracellular matrix (ECM) and enhanced AF vulnerability as a result of the altered myocardial substrate. 3 Another cause of AF is atrial tachycardia that leads to electric remodeling and altered intracellular Ca 2+ homeostasis associated with decreases in action potential duration (APD) and shortened atrial refractory periods (RPs). 4,5 Fibrosis is a hallmark of arrhythmogenic ECM remodeling, 6 occurs with alterations in connexin expression, and slows conduction velocity (CV), creating a barrier to impulse propagation by disrupting intermyocyte coupling. 6,7
Increased collagen deposition has been well documented in AF patients compared with control subjects. 8 Although the precise signaling processes of fibrosis are unknown, multiple factors have been implicated (eg, angiotensin II, transforming growth factor-β [TGF-β1], and platelet-derived growth factor) in the pathogenesis of atrial fibrosis. Angiotensinconverting enzyme overexpression is associated with atrial enlargement, atrial fibrosis, and AF, 9 whereas blockade of angiotensin-converting enzyme blunts atrial fibrosis and AF in animal models and patients with heart failure. 9 TGF-β1 and platelet-derived growth factor are thought to act on cardiac fibroblasts to increase collagen production without offsetting increases in collagen degradation. 5 It should be noted that the role of fibrosis as the cause of AF can be overstated because some studies show no difference in fibrosis in AF and control patients. 10 A possible explanation that remains unproven is that only some forms of collagen deposition cause AF, namely interstitial 11 and disorganized 12 collagen deposition promotes AF rather than surface collagen.
Current modalities for suppression of AF include drugs and ablation, each of which is limited by inefficacy, intolerance, and toxicity. Current drugs do not fundamentally alter the atrial substrate, whereas ablation requires destruction of viable tissue. Complications, costs, and difficulties associated with ablation have encouraged the development of better and safer drug therapies for the treatment of AF. 13, 14 Existing antiarrhythmic drug approaches have limited effectiveness and are associated with risks of serious complications, particularly ventricular proarrhythmia and organ toxicity. 2 The spontaneously hypertensive rat (SHR) has been widely studied as model of the effects of hypertension on the cardiovascular system. 15 In SHR, hypertension progresses as a function of age, is more pronounced in males than females, and exhibits most of the hallmarks of the human disease. 16 Previous studies on the SHR model have shown an increased incidence of AF and atrial tachyarrhythmias compared with normotensive Wistar-Kyoto (WKY) rats, attributed to greater levels of fibrosis. 17 These findings suggest that fibrosis may promote the development of AF, making it an important antiarrhythmic target.
Relaxin (RLX), a pleiotropic hormone, which is widely conserved, has been shown to have a wide range of biological actions, including anti-inflammatory, antiapoptotic, cardioprotective, vasodilatory, proangiogenic effects, and antifibrotic effects. 18, 19 RLX was first identified for its role in reproduction and pregnancy. It is thought to play a critical role in the hemodynamic adaptive and antifibrotic changes that occur during pregnancy. [19] [20] [21] Male RLX gene-deficient mice developed age-related cardiac fibrosis, ventricular stiffening, and diastolic dysfunction, suggesting an important role as an intrinsic regulator of collagen turnover. 22 In the present report, we demonstrate that exogenous systemic administration of RLX to SHRs suppresses AF inducibility by reversing fibrosis and hypertrophy and by increasing CV. These actions of RLX may be relevant to human AF, and as a proof of concept, we show that RLX upregulates I Na in human cardiomyocytes derived from inducible pluripotent stem cells (iPS-CMs) by a genomic mechanism.
Methods

Study Design
All animals received humane care in a facility, in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (publication 85-23, revised 1985). The study protocol was approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh. AF inducibility was studied in age-matched (9-12 months) and sex-matched (male) rats (Charles River Laboratories) that were separated into 4 groups: (1) normotensive WKY untreated rats; (2) untreated SHR; (3) SHR treated with the vehicle saline (SHR+V); and (4) SHR treated with RLX (SHR+RLX). Recombinant human RLX was supplied by Corthera-Novartis (Basel, CH). Osmotic mini-pumps (ALZET; Durect Corporation, model 2ML2) were used for the RLX and V treatment groups. Pumps were loaded with either recombinant human RLX solution (1.67 mg/mL) or V (20 mmol/L sodium acetate buffer, pH 5.0). The RLX infusion rate was ≈0.5 mg/kg per day (for 400 g rats) during the 14-day period. This dose of RLX is comparable with the dose previously used to treat in vivo rodent models of fibrosis [23] [24] [25] and to examine effects of RLX on arterial hemodynamics and vascular mechanical properties. 25, 26 Pumps were surgically implanted using sterile technique into the subcutaneous space on the left side of anesthetized animals. Animals were monitored during the 14 days of RLX or V delivery to confirm proper healing of the implant pocket. Experiments showed that rats treated with the saline vehicle had, as expected, similar electrophysiological properties as untreated rats, and as stated, data from the 2 groups were combined into some figures, which also allowed us to display the findings more clearly. For Western blot and reverse transcriptase polymerase chain reaction (RT-PCR) analysis, the 4 groups were WKY treated with vehicle (WKY+V) or relaxin (WKY+RLX) and SHR treated with vehicle (SHR+V) or relaxin (SHR+RLX).
Physiological Measurements
Blood pressure, heart rate, and serum RLX concentration were measured at 3 time points of the treatment as described in the Online Data Supplement: pretreatment (day 0), mid-treatment (day 7), and posttreatment (day 14). Hearts were perfused in a Langendorff apparatus to map action potentials (APs) and intracellular Ca 2+ transients simultaneously using standard techniques (see Online Data Supplement).
Programmed stimulation was used to test AF vulnerability; each heart was paced at the right atrium (RA) using a stimulation protocol consisting of 20 S1 pulses at 250 ms cycle length, followed by a premature S2 pulse (see Online Data Supplement). Maps of APs were used to calculate CV, generate activation maps, measure APD 90 , and investigate the nature of AF by time and frequency domain analysis using previously reported techniques (see Online Data Supplement). Transient AF lasted <3 seconds and self-terminated, whereas sustained AF lasted >3 minutes and was terminated by a bolus injection of KCl (1 mol/L) in the compliance chamber located above the aortic cannula to the heart. 
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Tissue Analysis
Atrial tissues were used to investigate changes in collagen deposition, connexin 43 phosphorylation, hypertrophy of cardiomyocytes, and transcripts for fibrosis as described in the Online Data Supplement. RT-PCR analysis was used to measure the expression levels of RNAs of interest, which were normalized to GAPDH. Primer pair sequences (forward and reverse for each target, listed 5′ to 3′) used for RT-PCR are given in the Online Data Supplement for matrix metalloproteinase (MMP)-2, collagen I, collagen III, TGF-β, and GAPDH.
Statistics
AF vulnerability between the different groups was compared using Fisher exact test. Parameters recorded under different S1-S2 were compared using ANCOVA. For RT-PCR, Western blot, and immunofluorescence microscopy, comparisons among ≥3 groups were performed using a nonparametric test (Kruskal-Wallis) with post hoc analyses (Conover). All results are reported as mean±SD unless otherwise stated. For all tests, a value of P<0.05 was considered to be statistically significant.
Results
AF Vulnerability
AF was inducible in each of the 5 SHR animals, but none of the 5 WKY animals (P<0.01; Figure 1 ). In WKY hearts, a premature impulse close to the RP (S1-S2=50 ms) captured and propagated, whereas still shorter intervals (S1-S2 <50 ms) failed to capture and did not induce AF (n=0/5; Figure 1Aa and 1Ab). In SHR hearts ( Figure 1B ), a premature impulse at S1-S2 of 75 ms captured and propagated normally (a), but a 70-ms S1-S2 interval induced a transient arrhythmia (b), and a still shorter interval produced sustained AF (c and d; n=5/5; P<0.01 versus WKY). In left atria (LA) while pacing at 250 ms cycle length, RPs were shorter than mean APD 90 (WKY: RP=40±13 ms, APD 90 =98±18 ms, n=5, P<0.05; SHR: RP=58±10 ms, mean APD 90 =87±18 ms, n=5, P<0.05). RPs were shorter in WKY versus SHR atria (n=5 each; P<0.01), and in SHR hearts, sustained AF was initiated at S1-S2 of 70±12 ms, which was not significantly different from their mean RP (n=5; P=NS). Figure 2 illustrates AP from an SHR heart before and during a transient AF (A) and during a sustained AF (B). Activation maps during transient (a-g) AF (A) exhibited a stable reentry pattern, with wavefronts emanating from a similar origin and propagating in a similar direction from beat to beat. In contrast, during sustained AF (Figure 2Ba′ -2Bg′), the origins of successive reentrant waves varied randomly and the arrhythmia was perpetuated by coexisting reentrant circuits maintained through the continuous annihilation and creation of daughter wavelets. 27 Voltage oscillations during AF were analyzed in time and frequency domains to visualize the evolution of AF frequencies. 27 The spectrogram (short-time Fourier transform) reveals coexisting reentrant circuits at different frequencies (9-20 Hz) and energy densities ( Figure 2C ). The analysis showed that the RA and LA had similar dominant frequencies (13.7±1.4 and 14.2±0.8 Hz; Figure 2D ). In SHR hearts, abnormalities in Ca 2+ homeostasis (eg, larger intracellular free Ca 2+ transients [Ca i ] T s and spark amplitudes, normal L-type Ca 2+ current density, I Ca,L , and absence of heart failure) have been attributed to cellular hypertrophy, resulting in altered coupling between Ca 2+ entry via I Ca,L and sarcoplasmic reticulum Ca 2+ release. 28 The altered sarcoplasmic reticulum Ca 2+ release in SHR hearts suggested a potential mechanism to initiate and sustain AF, which we tested by simultaneous mapping of APs and Ca i T to search for spontaneous (nonvoltage-dependent) Ca 2+ release and Ca i oscillations. As shown in the Online Data Supplement (Online Figure IIA) , Ca i followed membrane potential (V m ) during transient arrhythmia and sustained AF (Online Figure IIB) ; neither did Ca i oscillations occur that were not associated with voltage depolarizations (n=4/4 hearts).
Optical Mapping of AF
Effects of RLX Treatment on Blood Pressure, Heart Rate, Serum RLX, and AP
RLX was not detectable in the serum of animals, unless administered exogenously. In SHR+RLX rats, serum RLX measured on the final day of treatment was 70±9 ng/mL, whereas SHR+V rats had undetectable levels of RLX (P<0.001, see Online Figure IS ). Blood pressures were comparable between SHR+RLX and SHR+V animals at all time points, indicating that RLX did not reverse the hypertension (Online Table I ). RLX is known to cause an acute increase in heart rate, mediated by cAMP elevation consistent with our findings that RLX (100 nmol/L) perfusion increased heart rate by 10% to 15% within a minute (n=5 per group: SHR or WKY). A similar Figure 1 . Inducibility of atrial fibrillation (AF) in normotensive and hypertensive rats. A, Representative action potential (AP) traces from the left atria (LA) in normotensive Wistar-Kyoto (WKY) rat. As expected, a premature pulse with an S1-S2 interval of 50 ms is longer than the refractory period and captures (a), whereas S1-S2 of 45 ms is shorter than the refractory period and does not capture. No arrhythmias could be elicited by programmed stimulation or burst pacing. B, Representative AP traces from LA of spontaneously hypertensive rat (SHR). With a premature pulse at S1-S2 of 75 ms, a normal AP captures and propagates (a); an impulse delivered at a shorter interval of 70 ms elicits transient arrhythmia and when delivered at still shorter interval of 60 ms, sustained AF is induced (c), which persisted for the duration of the experiment (d).
increase in heart rate was found in SHRs in mid-treatment (1 week) and post-treatment (2 weeks) with RLX (Table I) .
The effects of RLX or V treatment on APD 90 , CV, and AP rise time on the LA of SHR hearts were measured as a function of cycle length and compared with values measured in untreated SHR and WKY hearts. These electric characteristics are shown for the LA in the Table, whereas the heart was paced on the RA. APD 90 were shorter in SHR than WKY (P<0.05), shorter in SHR+V than SHR (P<0.05), and shorter in SHR+LX than SHR+V (P<0.01) using ANCOVA.
CV was slower in SHR and SHR+V than WKY hearts, and SHR+RLX resulted in a marked increase in CV compared with WKY, SHR, and SHR+V (P<0.005; Table) . AP rise times tended to be shorter in SHR than WKY hearts, and SHR+RLX tended to reduce rise times further, but these changes did not reach statistical significance. While pacing on the RA, similar results were obtained on right atria (Online Table II . A, Activation pattern on a 100×100 pixel complementary metal-oxide-semiconductor with spatial resolution of 150×150 µm 2 exhibiting a single reentrant circuit during nonsustained AF. B, Activation pattern illustrating the creation and annihilation of multiple daughter waves (wavebreaks) during sustained AF. C, Timefrequency analysis of AF. The spectrogram was generated for each pixel by calculating the fast fourier transform (FFT) spectrum for a brief Gaussian window of 2 seconds, then shifting the window stepwise in time (Δt=1 ms) and remeasuring the FFT spectrum at successive t intervals. Top, Optical trace; left, overall FFT spectra; contour map, spectrogram with isolines drawn every 12.5% of maximum. Spectrogram plot frequency (ordinate) vs time (abscissa) and is shown for 14 seconds of AF; the darker the color, the higher the energy density at that frequency. D, Histogram represents the dominant frequencies during sustained AF in spontaneously hypertensive rats in the left atria (LA) and the right atrium (RA). In each left atria, AP rise time and APD 90 were measured from 10 pixels and averaged for 5 atria; CL, AP rise time, and APD 90 are in ms, CV in m/s, as means±SD. For WKY, SHR, and SHR+RLX, n=5 hearts and for SHR+V, n=4 hearts. AP indicates action potential; APD, AP durations; CL, cycle length; CV, conduction velocity; RLX, relaxin; SHR, spontaneously hypertensive rat; V, vehicle; and WKY, Wistar-Kyoto. *P<0.05 vs SHR. ‡P<0.05 vs WKY, SHR, and SHR+V (ANCOVA).
Effect of RLX on AF Inducibility
A major and consistent finding was that RLX treatment of SHR for 2 weeks suppressed AF inducibility (n=7/8; 1 heart had an infarct; Figure 3A and 3B). In contrast, V treatment of SHR failed to suppress AF inducibility (n=4/4; P<0.01 versus SHR+RLX; Figure 3C and 3D). More robust attempts to elicit AF in RLXtreated SHR hearts, such as varying the location of the pacing electrode and burst pacing (10 stimuli, 10-ms apart) on either the RA or LA, failed to elicit AF. In rare cases, the S2 impulse produced a nonsustained arrhythmia of <10 beats ( Figure 3A) . The mean RFs for SHR+V (51±4.3 ms; n=4) and SHR+RLX (50±10 ms; n=5) LA were not significantly different (P=NS). CV and APD restitution kinetics (RK) were measured from the RA and LA of WKY, SHR (untreated and treated with vehicle were combined), and SHR+RLX. Figure 4 (right) shows a marked effect of RLX on the CV RK of LA and RA compared with SHR hearts-namely, a large increase in CV particularly for short S1-S2 intervals and a less-steep RK curve. RLX treatment did not significantly alter the slope of APD RK curves (left) for LA and RA. RLX-treated SHR hearts had shorter APD 90 RK curves compared with SHR+V and WKY hearts, consistent with APD 90 in the Table. Activation maps of paced beats (S1), the premature beat (S2), and the first spontaneous beat are shown for an SHR+V and an SHR+RLX atrium (Online Figure IIIA and IIIB, respectively). The slower CV of the premature pulse and of the first spontaneous reentrant beat in SHR+V atria helps to sustain AF.
Histologic Findings
Differences in the level of fibrosis in the LA and RA of the different groups are shown in Figure 5 . SHR had a significantly greater collagen-to-tissue ratio in both the RA and LA compared with WKY (P<0.05). There was no significant difference in collagen-to-tissue ratio in both the RA and LA between SHR and SHR+V. However, RLX treatment attenuated the fibrosis within 2 weeks because SHR+RLX had a significantly lower collagen-to-tissue ratio compared with SHR and SHR+V (P<0.05). SHR+V LA cardiomyocytes had a significant level of hypertrophy, with greater cross-sectional area of LA myocytes (cross-sectional area=146.9±07.2 µm 2 ) compared with WKY+V (95.5±10.6 µm 2 ; P<0.01). The cross-sectional area of WKY+RLX atrial myocytes (96.9±3.3 µm 2 ) did not differ from that of WKY+V. However, the cross-sectional area of LA cardiomyocytes from SHR+RLX was significantly less (100.8±2.98 µm 2 ; P<0.05) than that of SHR+V and not significantly different from either WKY group. Thus, RLX seemed to reverse atrial myocyte hypertrophy in SHR hearts.
Effect of RLX on Connexin 43 Phosphorylation and Fibrosis-Related Transcripts
The effect of RLX treatment on the relative phosphorylation of connexin 43 in SHR RA was assessed by Western blot analysis, using the differential molecular weight of phosphorylated (43 kDa) to nonphosphorylated connexin 43 (40 kDa). Proteins from relaxin-treated SHR showed a significantly greater ratio in the band intensity of the 43-to 40-kDa proteins (SHR+RLX, 5.74±1.46; SHR+V, 2.15±1.26; n=4/group; P<0.01).
The effect of RLX versus V treatment on fibrosis-related transcripts was examined by RT-PCR from RNA isolated from the LA of 4 to 5 rats per group (WKY+V, WKY+RLX, SHR+V, SHR+RLX; Figure 6 ). TGF-β, MMP-2, MMP-9, collagen I, and collagen III transcripts were all significantly elevated in SHR+V versus WKY+V (P≤0.05). In WKY, RLX treatment did not alter fibrosis-related transcripts ( Figure 6 ). In contrast, RLX treatment significantly reduced all the transcripts, except for collagen III, which exhibited a marked trend toward a decrease. For TGF-β, MMP-2, and MMP-9, transcripts levels in SHR+RLX were not different from their levels in WKY+V or WKY+RLX groups. Collagen I transcripts levels, while significantly reduced relative to SHR+V, remained somewhat elevated relative to WKY groups. Collagen III transcripts followed a similar pattern.
RLX Upregulates I Na in Human iPS-CMs Independent of Fibrosis
A main electrophysiological change caused by RLX is a marked increase in CV, which is difficult to attribute solely to reduced fibrosis and altered expression, localization, and phosphorylation of connexin 43. Alternatively, large increases in CV are more readily caused by an increase in current density of voltage-gated sodium channels, I Na . To test the effects of RLX on I Na and the relevance of our findings in rat hearts to human hearts, we tested the effects of RLX on I Na density in human iPS-CMs. Human iPS-CMs were cultured with vehicle or 0.1 µmol/L RLX for 48 hours, and then I Na density was measured using the whole-cell voltage-clamp technique (see Methods in the Online Data Supplement). Treatment of human iPS-CMs with RLX increased the peak I Na density by ≈2-fold without altering the characteristics of the current-to-voltage relationship (Figure 7) . RLX did not alter I Na , acutely requiring ≥24 hours to upregulate the current. Human iPS-CMs largely represent mature human ventricular myocytes that exhibit low levels of inwardly rectifying K + current. 29, 30 RLX (100 nmol/L) was also found to upregulate I Na A, An example of a nonsustained AF initiated by a single premature pulse using a short delay, S1-S2=35 ms. B, In most SHR+RLX hearts, no arrhythmias were elicited by a premature impulse, and at S1-S2 of 30 ms the premature impulse failed to capture (n=7/8). Activation maps from an SHR+RLX heart at 250 ms (C) and 90 ms (D) S1-S2 interval; note the rapid propagation of the premature impulse in D. density of guinea pig atrial myocytes in 24 to 72 hours (data not shown). The time needed to enhance I Na in cultured iPS-CMs is a strong indicator of a genomic upregulation of Nav1.5 that occurs independently of the antifibrotic effects of RLX and provides a compelling proof of concept that RLX may suppress AF in human hearts.
Discussion
The main findings are that SHR hearts have a higher susceptibility to AF triggered by a single premature impulse. SHR atria had a slower CV and higher levels of collagen deposition (ie, fibrosis). RLX treatment of SHR animals for 2 weeks significantly reversed fibrosis and hypertrophy, increased atrial CV, and suppressed AF.
Atrial Fibrosis and AF
Atrial fibrosis has been implicated in the pathogenesis of AF, but a direct link between fibrosis and AF has not been established. Atrial tissue fibrosis is nevertheless a most consistent finding in patients and animal models of AF. 31 Our histological studies confirm that SHR hearts are fibrotic and hypertrophic compared with controls. In addition, SHR atria are characterized by conduction abnormalities that provide a basis for lines of conductional block that promote reentry as seen in optical mapping studies. The major mechanisms that have been proposed for the initiation and maintenance of AF are the multiple wavelet theory, 32 focal activity hypothesis, 33 and single-circuit reentrant theory. 34 Our optical mapping studies were consistent with AF generated by coexisting reentrant circuits with varying origins, which supports the multiple wavelet theory as the mechanism of AF.
Antifibrotic and Antiarrhythmic Properties of RLX and Its Clinical Relevance
Relaxin mediates effects on the cardiovascular system by activating a wide range of signaling pathways via the relaxin family peptide receptor 1, a G-protein-coupled receptor that leads to an acute elevation of cAMP and nitric oxide. 19, 35 In other . Restitution kinetics of action potential duration (APD) and conduction velocity (CV). A and B, Restitution kinetics (RK) measured from the left atrium (LA) for CV and APDs at 90% recovery to baseline (APD 90 ), respectively. CV and APD 90 were measured as a function of S1-S2 interval. For APD 90 : Wistar-Kyoto (WKY) vs spontaneously hypertensive rat (SHR), P=NS; SHR vs SHR+vehicle (V), P<0.01; and SHR vs SHR+relaxin (RLX), P<0.01. For CV: WKY vs SHR, P<0.05; SHR vs SHR+V, P=NS; SHR vs SHR+RLX, P<0.01. C and D, RK from the right atrium (RA) for CV and APD 90 , respectively. CV and APD were measured as a function of S1-S2 interval. APD 90 : WKY vs SHR, P<0.0; SHR vs SHR+V, P<0.01; SHR vs SHR+RLX, P<0.01. CV: WKY vs SHR, P<0.01; SHR vs SHR+V, P=NS; SHR vs SHR+RLX, P<0.01. All values are reported as mean±SD. studies, RLX has been shown to inhibit fibroblast proliferation, differentiation, collagen synthesis, collagen deposition, and increased MMP-2 expression, which most likely contributed to an increase in collagen degradation and a decrease in collagen deposition. 36 Our results demonstrate the increased collagen I deposition, transcripts encoding the profibrotic cytokine TGF-β, the major ECM fibrotic component collagen I, and MMP-2 and -9 in SHR atria relative to normotensive WKY, similar to previous reports for SHR left ventricle and atrial tissues. 17, 37 We also observed a relaxin-induced decrease in atrial collagen I and collagen transcripts and TGF-β transcripts, similar to that reported for the SHR-LV and in a model of interstitial renal fibrosis, 23, 24, 38 and consistent with a role for inhibition of TGF-β expression or signaling in the reversal of cardiac (and other organ) fibrosis by RLX. 39 We observed a decrease in RNA encoding MMP-2 and MMP-9 in response to RLX treatment, whereas an increase in MMP-2 activity has been previously observed in SHR ventricles treated with RLX. 24 However, our observations are consistent with reports that in atria from rats or dogs subjected to interventions that increase AF susceptibility, fibrosis and MMP expression/ activity were both elevated 40, 41 and that MMP inhibition reversed atrial cardiomyocyte hypertrophy, MMP activity, collagen deposition, and AF inducibility. 41 Clearly, a more complete mechanistic understanding of the reversal of atrial fibrosis by RLX will require a broader examination of the activity of multiple MMPs and of their endogenous inhibitors (tissue inhibitors of metalloproteinases).
Targeting fibrosis has been attempted with angiotensinconverting enzyme inhibitors, angiotensin receptor blockers, and a novel compound pirfenidone. However, most of these studies have examined models of heart failure, which is less commonly associated with AF than hypertension. Pirfenidone has been shown to reverse fibrosis and attenuate AF in a congestive heart failure canine model. 42 Pirfenidone treatment achieved reversal of atrial fibrosis and reduced vulnerability of AF after burst pacing but did not generate a significantly greater increase in atrial CV. In contrast, our data show that treatment with RLX reduces AF inducibility, reverses atrial fibrosis and hypertrophy, increases CV, and decreases APD.
It is important to note that RLX treatment of SHRs for 1 week was ineffective in suppressing AF and that longer RLX treatment was necessary because remodeling of the ECM and gap junctions may be reversed, albeit slowly. Reversal of fibrosis is a slow process as a result of the slow collagen turnover rate of 5% per day in healthy hearts. 43 Enhanced atrial fibrosis can in turn alter connexin 43 expression and its redistribution to lateral cell borders, creating a barrier to impulse propagation by reducing intermyocyte coupling and CV. 6 However, it is difficult to evaluate the amount of connexin disruption that is required to produce a significant change of CV, and an alternative mechanism is to increase CV by an upregulation of I Na density. The pleiotropic effects of RLX and its relevance to human hearts were demonstrated by testing its effects on cultured human iPS-CMs. Independent of fibrosis, RLX increased sodium current density in 48 hours, indicating that RLX acted at fibroblasts to remodel ECM and human myocytes to alter ion channel expression.
The actions of 2 weeks of RLX treatment differ from the acute effects of RLX. In rat hearts, RLX was found to bind to atrial tissue, 44 increase heart rate, 45 prolong APD by inhibiting the I t.o K + current, 46 and increase Ca 2+ influx because of APD prolongation. 47 The acute effect of RLX on heart rate was readily measured in perfused hearts, but the longer-term effects of RLX on increased atrial CV and reduced APD 90 relative to SHR+V controls imply additional direct effects on ion channel properties and expression, as well as its antifibrotic effects.
Efficacy and Safety
RLX has been under clinical trials for acute heart failure with a completed 234-patient phase 2 and an ongoing 160-patient phase 3. 48 Reports have confirmed the safety of RLX infusion in humans (≤0.96 mg/kg per day) and have noted a vasodilatory effect in patients with heart failure, but RLX therapy did not always improve renal functions. 49 The clinical trials to date have sensibly addressed potential benefits of short-term treatment in vasodilation, but have not examined whether other pathways mediated by RLX can be exploited to provide longterm therapeutic benefits.
Limitations
Our studies used the SHR model that exhibits many parallels to human hypertension. 50 However, ECM remodeling in hypertension and mechanisms of AF may differ in rats and humans. The exact mode of action of RLX at suppressing AF is complex; RLX has the anticipated antifibrotic effects on the atria, but reversal of fibrosis may not be sufficient to explain the marked increase in CV, which is the predominant mechanism for AF suppression. As proof of concept that RLX modulates cardiac properties independent of fibrosis and is relevant to human AF, we tested the effects of RLX on the voltage-gated sodium current in cultured human iPS-CMs. RLX treatment for 48 hours markedly upregulated I Na density (from −22.95±5.8 to −38.64±10 pA/pF, mean±SEM) most likely by a genomic mechanism that could explain the increase in CV and faster AP rise time. Hence, longer-term treatment with RLX suppresses AF, in part, by reversing fibrosis, enhancing connexin 43 phosphorylation, and upregulating voltage-gated Na + channels. Still other contributing factors cannot be excluded, and further studies will be needed to fully characterize the panoply of the actions of RLX.
Possible adverse effects of RLX cannot be excluded, and the cardiovascular safety of RLX will have to be stringently tested before RLX can be a game-changing therapy for the treatment of AF.
What Is Known?
• Major risk factors for atrial fibrillation (AF) include sex (men>women), old age, hypertension, and enhanced tissue fibrosis. • Fibrosis is thought to be arrhythmogenic, as it correlates with altered connexin expression, hypertrophy, and a slowing of conduction velocity. • AF therapy is often ineffective; treatments with drugs and ablation are limited by intolerance, toxicity, and destruction of viable tissue.
What New Information Does This Article Contribute?
• Systemic administration of the pleiotropic hormone relaxin for 2 weeks suppresses AF inducibility in spontaneously hypertensive rat hearts. • Relaxin acts by reversing fibrosis and myocyte hypertrophy in atrial tissue and increasing conduction velocity, and in cultured human myocytes derived from stem cells, relaxin increases the sodium current, which is consistent with the increase in conduction velocity. • The effects of relaxin on rat atrial tissue and human myocytes are proof of concept for a new approach to remodel heart tissues and develop more effective therapy for AF patients.
AF is a serious public health problem in dire need of new solutions because current treatments involve either the destruction of viable tissue (ablation) or the risk of cardiac toxicity (drug therapies). In spontaneously hypertensive rats, sustained AF is readily elicited by a single premature impulse. We report here that a 2-week treatment with the reproductive hormone relaxin suppresses AF in spontaneously hypertensive rat hearts by reversing fibrosis and myocyte hypertrophy and causing a marked increase in conduction velocity. In models of hypertension and age-related AF, a slowing of conduction velocity has been associated with AF vulnerability. The possibility that relaxin increases conduction velocity by acting directly on myocytes was tested in cultured human cardiomyocytes derived from inducible pluripotent stem cells, where relaxin increased the magnitude of the voltage-gated Na + current density, I Na by 2-fold in 48 hours, which is consistent with the higher conduction velocity. These findings indicate that relaxin acts on the extracellular matrix through fibroblast modifications and directly on myocyte level. The antifibrotic and antihypertrophic actions of relaxin and its genomic upregulation of I Na provide compelling evidence that relaxin may provide a novel and transformative therapy to treat AF.
Novelty and Significance
